We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64;PATHVACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02515227
Recruitment Status : Completed
First Posted : August 4, 2015
Last Update Posted : November 17, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia

Brief Summary:
This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.

Condition or disease Intervention/treatment Phase
Melanoma Biological: 6MHP Drug: Pembrolizumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
Study Start Date : November 2015
Actual Primary Completion Date : March 14, 2020
Actual Study Completion Date : March 14, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma Vaccines

Arm Intervention/treatment
Experimental: 6MHP + Pembrolizumab
6 MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
Biological: 6MHP
6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Other Name: 6 melanoma helper peptide vaccine

Drug: Pembrolizumab
Humanized monoclonal antibody (mAb) specific for PD-1.
Other Names:
  • MK-3475

Primary Outcome Measures :
  1. Adverse event profile for the combination of pembrolizumab and 6MHP. [ Time Frame: 30 days after the last administration of study drug. ]
  2. CD4+ T cell responses in the blood [ Time Frame: through week 104 ]
    Measurements of CD4+ T cell responses to the peptide vaccine.

Secondary Outcome Measures :
  1. Number of T cells in the tumor microenvironment [ Time Frame: up to week 104 ]
    Evaluation of tumor infiltration by CD4+ and CD8+ T cells.

  2. Level of Th1-dominant immune signatures in the tumor microenvironment [ Time Frame: up to week 104 ]
    Evaluation of cytokine profile for CD4+ T cells.

  3. Number of CD8+ T cell responses to defined melanoma antigens [ Time Frame: up to week 104 ]
    Evaluation of epitope-spreading through the measurement of the induction of CD8+ T cell responses to defined melanoma antigens.

  4. Amount of IgG antibody specific for 6MHP as measured in the blood and the sentinel immunized node [ Time Frame: up to week 104 ]
    Evaluation of antibody responses to 6MHP

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects with unresectable stage IIIB or IIIC melanoma, or stage IV metastatic melanoma that have clinical or radiological evidence of disease. Subjects may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma. Staging must be confirmed by cytological or histological examination. Staging of cutaneous melanoma will be based on the revised AJCC staging system
  2. Ability to provide written informed consent/assent for the trial.
  3. ≥18 years of age
  4. A subject may be naïve for immunotherapy agents or have received interferon-alpha, ipilimumab or other CTLA-4 antibody, PD-1 antibody (or anti-PD-L1 antibody), interleukin-2, or prior cancer vaccines other than the 6MHP vaccine. Patients who have received a PD-1/PD-L1 antibody may be enrolled in either of the following settings:

    1. A patient who has experienced progression of melanoma during that therapy or after having completed that therapy,
    2. A patient who fails to experience an objective clinical response (partial response or complete response by RECIST 1.1 criteria) after either 12 weeks of continuous anti-PD1 antibody or anti-CTLA4/anti-PD1 combination therapy, and is a candidate to receive pembrolizumab therapy
  5. Measurable disease based on RECIST 1.1.

    Subjects will be required to have radiological studies to define radiologically evident disease. Required studies include:

    • Chest CT scan,
    • Abdominal and pelvic CT scan, and
    • Head CT scan or MRI PET/CT fusion scan may replace scans of the chest, abdomen, and pelvis.
  6. Subjects who have metastatic melanoma available for biopsy pretreatment and on day 22 must consent to having those biopsies. These metastases may be in nodes, skin, soft tissue, liver, or other sites that can be accessed safely by needle biopsy, incisional or excisional biopsy, with or without image guidance. The lesions to be biopsied must be specified at study enrollment and not included as target lesions for RECIST calculations. In instances where disease that is accessible to biopsy is limited, archival tissue specimens collected after a subject's last systemic therapy may be used for baseline measures.

    Subjects must have measurable disease in addition to the lesion(s) to be biopsied.

  7. Subjects who have had brain metastases will be eligible if all of the following are true:

    • Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery.
    • There has been no evident growth of any brain metastasis since the most recent treatment
    • No brain metastasis is > 2 cm in diameter at the time of registration.
    • Neurologic symptoms have returned to baseline,
    • There is no evidence of new or enlarging brain metastases,
    • Subjects are not using steroids for at least 7 days prior to registration.
  8. The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ≥ 1 week prior to registration.
  9. ECOG performance status of 0 or 1
  10. Adequate organ function.
  11. Two intact (undissected) axillary and/or inguinal lymph node basins.

Exclusion Criteria

  1. Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
  2. Is currently receiving Interferon (e.g. Intron-A®), growth factors (e.g. Procrit®, Aranesp®, Neulasta®), or interleukins (e.g. Proleukin®), or has received these agents within 4 weeks of the first dose of treatment.
  3. Is currently receiving nitrosureas or has received this therapy within the preceding 6 weeks of first dose of treatment.
  4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment with the following exceptions (which are permitted):

    • replacement steroid doses in patients with adrenal or pituitary insufficiency
    • Intra-articular steroid injections
    • Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) at low doses (less than 500 mcg fluticasone per day, or equivalent)
    • Topical and nasal corticosteroids
    • Non-steroidal anti-inflammatory drugs
  5. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
  6. Has had prior chemotherapy, targeted small molecule therapy, or external beam radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.

    • Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
    • Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include carcinoma in situ of the breast (DCIS or LCIS), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  9. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions to this criterion include:

    • Subjects with vitiligo or other depigmenting illness.
    • Resolved childhood asthma/atopy
    • Intermittent use of bronchodilators or local steroid injections
    • Hypothyroidism stable on hormone replacement or Sjogren's syndrome
    • The presence of laboratory evidence of autoimmune disease (e.g. positive ANA titer) without symptoms
    • Mild arthritis requiring NSAID medications
  10. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
  11. Has an active infection requiring systemic therapy.
  12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  15. Is HIV positive or has evidence of active Hepatitis C virus (testing to be done within 6 months of study entry) or active Hepatitis B virus.
  16. Has received a live vaccine or allergy desensitization injections within 30 days prior to the first dose of trial treatment.
  17. Has known or suspected allergies to any component of the vaccine.
  18. Has been vaccinated previously with any of the synthetic peptides included in this protocol.
  19. Is classified according to the New York Heart Association classification as having Class III or IV heart disease (Appendix 12.5).
  20. Has uncontrolled diabetes, defined as having a HGBA1C > 7.5%.
  21. Has a body weight < 110 pounds (without clothes) at enrollment, due to the amount and frequency with which blood will be drawn.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02515227

Layout table for location information
United States, Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Craig L Slingluff, Jr
National Cancer Institute (NCI)
Layout table for investigator information
Study Director: Craig L. Slingluff, Jr., MD University of Virginia
Layout table for additonal information
Responsible Party: Craig L Slingluff, Jr, Director, Human Immune Therapy Center, University of Virginia
ClinicalTrials.gov Identifier: NCT02515227    
Other Study ID Numbers: 18174
R01CA178846 ( U.S. NIH Grant/Contract )
First Posted: August 4, 2015    Key Record Dates
Last Update Posted: November 17, 2020
Last Verified: November 2020
Keywords provided by Craig L Slingluff, Jr, University of Virginia:
Montanide ISA-51
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Antineoplastic Agents